|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||35.19 - 36.89|
|52 Week Range||9.85 - 42.36|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.30|
Shareholders of Arcus Biosciences, Inc. ( NYSE:RCUS ) will be pleased this week, given that the stock price is up 11...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 31,400 shares of the Company’s common stock at an exercise price per share of $33.28, which was the closing price on February 23, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided operational highlights.